Strengthening the research and development structure through the establishment of a drug discovery research center
First written in FY2019-Q1. 3 of 6 entries say "Advanced", first in FY2019-Q2. Latest entry: FY2020-Q2.
No other company in this theme has enough history to compare yet.
- FY2020-Q2AdvancedAnnual report
「In November 2019, the company began operating the newly established Drug Discovery Research Institute, further strengthening its R&D capabilities toward license agreements for its drug discovery pipeline.」
The disclosure states that the Drug Discovery Research Institute, whose construction had been completed, began operations in November 2019. - FY2020-Q1AchievedAnnual report
「This was mainly due to a ¥742 million decrease in cash and deposits resulting from advertising investment and payments for the construction of the drug discovery research center, a ¥434 million increase in notes and accounts receivable resulting from higher sales in the mail-order business, and a ¥480 million increase in property, plant and equipment following completion of construction of the drug discovery research center.」
Completion of construction of the Drug Discovery Research Institute was disclosed, indicating that the project had reached the actual completion stage beyond the previously scheduled completion date. The main facilities table also lists October 2019 as the completion month. - FY2019SoftenedAnnual report
「Drug Discovery Research Institute (Nishikyo-ku, Kyoto) Biomedical Business Research and development 1,000,000 221,800 Internal funds and borrowings December 2018 October 2019 Strengthening the R&D structure」
The amount already paid for the Drug Discovery Research Institute increased from ¥65 million to ¥221.8 million, while the scheduled completion date was pushed back from August 2019 to October 2019. - FY2019-Q3AdvancedAnnual report
「Drug Discovery Research Institute (Nishikyo-ku, Kyoto) Biomedical Business Research and development 1,000 65 Internal funds and borrowings December 2018 August 2019 Strengthening the R&D structure」
For the plan to establish the Drug Discovery Research Institute, the amount already paid increased from ¥62 million to ¥65 million. The total cost of ¥1,000 million and scheduled completion in August 2019 remain unchanged. - FY2019-Q2AdvancedAnnual report
「Drug Discovery Research Institute (Nishikyo-ku, Kyoto) Biomedical Business Research and development 1,000 62 Internal funds and borrowings December 2018 August 2019 Strengthening the R&D structure」
For the plan to establish the Drug Discovery Research Institute, work began in December 2018 and the amount already paid was ¥62 million. The total cost is ¥1,000 million, with completion scheduled for August 2019. - FY2019-Q1First statedAnnual report
「Company name Business site (Location) Segment name Description of facilities Planned investment Funding method Start date Scheduled completion Post-completion capacity increase Total (¥ million) Amount already paid (¥ million) Filing company Drug Discovery Research Institute (Nishikyo-ku, Kyoto) Biomedical Business Research and development 1,000 － Internal funds and borrowings December 2018 August 2019 Strengthening the R&D structure」
The company is establishing a Drug Discovery Research Institute at a total cost of ¥1,000 million, with construction scheduled to begin in December 2018 and be completed in August 2019. The post-completion capacity increase is described as strengthening the R&D structure.